SUNDAY, FEBRUARY 21
Arrival and Registration

MONDAY, FEBRUARY 22
Welcome and Keynote Address
Pamela J. Bjorkman, California Institute of Technology, USA
A Molecular Arms Race: The Immune System versus HIV

Human Immunization
William Schief, International AIDS Vaccine Initiative and The Scripps Research Institute, USA
Clinical Tests of Germline Targeting
Julie Ledgerwood, NIAID, National Institutes of Health, USA
VRC01 Clinical Trials
M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Env Based Immunogenicity in the Clinic
Short Talks Chosen from Abstracts

Passive Therapies
Glenda E. Gray, South African Medical Research Council, South Africa
The AMP Study
Marina F. Caskey, Rockefeller University, USA
Human Studies with Combination bNAbs
Katharine Bar, University of Pennsylvania, USA
Treatment Interruption after bNAb Administration
Short Talks Chosen from Abstracts

Poster Session 1

TUESDAY, FEBRUARY 23
Vaccine Immunology
Speaker to be Announced
Speaker to be Announced

Gabriel D. Victora, Rockefeller University, USA
Germinal Center Dynamics
Facundo D. Batista, Massachusetts Institute of Technology and Harvard University, USA
Mouse Models for HIV-1 Vaccines
Short Talks Chosen from Abstracts

Immunization Strategies
Neil P. King, University of Washington, USA
Design of Self-Assembling Protein Nanomaterials for Structure-Based Vaccine Design
Shane Crotty, La Jolla Institute for Immunology, USA
Increasing the Breadth and Potency of Candidate HIV Vaccine Immune Responses
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Adjuvants in HIV-1 Vaccination
Short Talks Chosen from Abstracts

Poster Session 2

WEDNESDAY, FEBRUARY 24
HIV Immunology
Penny L. Moore, University of the Witwatersrand and National Institute for Communicable Diseases, South Africa
Viral vs. Antibody Diversification during Infection
Alexandra Trkola, University of Zürich, Switzerland
Role of the Virus in Dictating the Immune Response
Beatrice H. Hahn, University of Pennsylvania, USA
Exploiting the Ape Precursors of HIV-1 for AIDS Vaccine Design
Catherine A. Blish, Stanford University School of Medicine, USA
Targeting Natural Killer Cells to HIV
Short Talks Chosen from Abstracts

Control of Latency
Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
The Nature of the Latent Reservoir
Mary Carrington, NCI, National Institutes of Health, USA
Immunogenetic Variation in Outcome to HIV Therapy
Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
How Elite Controllers Control
Short Talks Chosen from Abstracts

Poster Session 3

THURSDAY, FEBRUARY 25
Cure Related Human Trials
Malcolm A. Martin, National Institutes of Health, USA
Antibody Studies in SHIV Infected Macaques
Romas Geleziunas, Gilead Sciences, Inc., USA
Developing Combination Therapies for Cure
Sharon R. Lewin, University of Melbourne, Australia
The Latent Reservoir
Sarah Fidler, Imperial College Faculty of Medicine, UK
Clinical Interventions and Their Effects on Viral Rebound
Short Talks Chosen from Abstracts

Session Title to be Determined
Peter D. Kwong, NIAID, National Institutes of Health, USA
HIV-1 Vaccination Targeting Specific Sites of Vulnerability
Rogier W. Sanders, University of Amsterdam and Weill Cornell Medical College, Netherlands
SOSIP Based Immunogens as Vaccines
Christopher O. Barnes, California Institute of Technology, USA
Structures of HIV-1 Env Trimers Define Antibody-Mediated Neutralization of HIV-1
Short Talks Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, FEBRUARY 26
Departure